

National Institute for Health and Clinical Excellence

Medicines Concordance Stakeholder Comments

1. Please put each new comment in a new row.
2. Please do not paste other tables into this table, as your comments could get lost – type directly into this table.
3. Please fill in the document you are commenting on in the first column, for example, the **Full version**, or the **Appendices to full version**
4. Please insert the **Page number (given at the bottom of the page)** in the 2nd column and the **Line Number** (given at the far left of the document). If your comment relates to the document as a whole, please put **'general'** in this column. **Please refer page numbers not section numbers.**
5. When commenting on the **Full version** please insert the **line number** in the 3rd column of the table below.

Name:		John Goddard		
Organisation:		British Pain Society		
Document.	Order Number	Page Number	Line Number	Comments
Indicate if you are referring to the Full version , or the Appendices to full version .	Please number your comments if making more than one	Indicate Page number or 'general' if your comment relates to the whole document. Please do not include any non-numerical text (eg the word 'page') in these boxes unless comment is general.	When commenting on the full version indicate the line number . Please do not include any non-numerical text (eg the word 'line') in these boxes	Please insert each new comment in a new row.
NICE Guideline	1	General		Nowhere in the document does it appear to mention that the information provided should be relevant to the condition being treated. This is particularly pertinent to the practice of pain medicine, where many drugs are used off-license. In the introduction (page 4) it states that "the guideline will assume that prescribers will use a drug's summary of product characteristics to inform their decisions for individual patients". It is our view that further clarification is required for off-license prescribing.
Full	2	154	4	We note the GDG concerns and that they were reassured – "The GDG considered it important to reassure clinicians that increasing patient involvement may not affect consultation times". Nonetheless, reassurance is only that it <u>may not</u> affect consultation times. Looking at the table, it would seem that, in the UK, two RCTs found no increase

PLEASE NOTE: The Institute reserves the right to summarise and edit comments received during consultations, or not to publish them at all, where in the reasonable opinion of the Institute, the comments are voluminous, publication would be unlawful or publication would be otherwise inappropriate.